## These images of diabetic retinopathy tell the story better

I read, with great interest, Dr. Farford's thorough review article "Diabetic retinopathy: the FP's role in preserving vision" (*J Fam Pract*. 2020;69:120-126). I am a family physician with ophthalmology training. For more than 20 years, I have regularly performed dilated eye exams and reviewed nonmydriatic fundus photos for uninsured patients with diabetic retinopathy (DR) at the community health clinic where I work. The burden of visual loss from poorly controlled diabetes is staggering.

I do, however, want to point out some inaccuracies in the labeling of 2 of the photos included in TABLE 1.


> The photo labeled "Severe NPDR [nonproliferative DR]"—FIGURE 1A actually shows an eye that has been

treated with panretinal photocoagulation (multiple laser scars present in all quadrants) with nice regression of DR. Along the superior temporal arcade there is fibrosis, which likely represents regression of vitreal neovascularization or resolution of vitreal hemorrhage. There is little apparent active DR in this photo. The caption indicated the presence of intraretinal microvascular abnormalities; however, while these abnormalities *may* be present, they are not evident due to the photo resolution.


The photo labeled "Proliferative diabetic retinopathy"—FIGURE 2A—does not show evidence of neovascularization of the disc or the retina. This photo would be more accurately labeled

### **FIGURE**









"severe DR with likely clinically significant macular edema."

The 2 photos shown here, from my photo collection, are perhaps more instructive:

- FIGURE 1B is an example of severe NPDR and maculopathy (this eye has undergone previous panretinal photocoagulation, a treatment option for severe NPDR and proliferative DR [defined as new vessel growth or neovascularization]).
- FIGURE 2B is an example of proliferative DR with vitreal hemorrhage that can lead to irreversible visual loss via traction retinal detachment.

I appreciate your efforts in publishing Dr. Farford's article. DR is a broad, complicated topic, and this informative article will help many FPs.

**Kenneth Libre, MD** Central City Community Health Center Salt Lake City, UT

# Putting an end to chronic opioid prescriptions

Thanks to Dr. Linn et al for "Tips and tools for safe opioid prescribing" (*J Fam Pract*. 2020;69:280-292), which addressed an important topic: the risks of, and poor evidence for, chronic opioids in noncancer pain.

Pain management is challenging, and it is easy to prescribe opioids from a desire to help. However, we must translate the evidence of chronic opioids' poor benefit and real harms into practice. No studies show a long-term benefit of opioids for chronic noncancer pain, but they do demonstrate abundant findings of harm. As a family medicine community, we should be practicing at the highest level of evidence and addressing legacy opioid prescribing for chronic noncancer pain.

Increasing opioid doses for pain only offers short-term benefits and can result in rapid tolerance and withdrawal. We should not be starting people on opioids for knee and back pain. We do not need more ways to initiate opioids or tables on how to dose long-acting opioids—drugs that increase mortality. Let's stop using poorly validated tools like DIRE to ignore the evidence against

opioids (validated with 61 retrospective chart reviews; 81% sensitivity, 76% specificity for predicting efficacy of opioids).<sup>2,3</sup>

A 2018 randomized controlled trial of 240 patients with back, knee, or hip osteoarthritis found opioids were not superior to nonopioid medication for pain-related function at 12 months and had more adverse effects. A 2015 systematic review concluded there was insufficient evidence of long-term benefits of opioids but a dose-dependent risk of serious harm. Just 1 year of taking low-dose opioids can increase the risk of opioid use disorder by 0.7%, compared with 0.004% with no opioids. 5

Practical approaches exist. Excellent examples of modern pain care have been developed by the Department of Veterans Affairs/ Department of Defense, the Department of Health and Human Services, and state-level initiatives such as the Oregon Pain Guidance. All use a similar clinical algorithm (FIGURE). If pain is poorly controlled, a slow medically supervised tapering of opioids is indicated.

It can be challenging to raise the subject of opioid tapering with patients; I use Stanford's BRAVO method to guide these conversations. At my facility, we are tapering about 50 legacy opioid patients, and most are surprised to find that their pain is the same or better with reduced to no opioids, with fewer adverse effects. Many are happier on sublingual buprenorphine, a safer opioid analgesic. The algorithm shown in the FIGURE and the BRAVO method should be more widely used within our specialty for a safe and patient-centered approach to chronic pain.

Above all, let the patient know that you are with them on this journey to safe pain management. Start the conversation: "I've been thinking a lot about your chronic pain and how best to help you with it. Our understanding of what opioids do for pain has changed, and I worry they're causing more harm than good now. This is a scary thing to talk about, but I'll be with you every step of the way."

Matt Perez, MD
Neighborcare Health
Seattle

We should not be starting people on opioids for knee and back pain. Start the pain management

conversation

by saying: "I've been thinking a lot about your chronic pain

and how best

that opioids are


causing more harm than good

now."

to help you with it. I worry

#### **FIGURE**

### Chronic Pain Evaluation and Management Algorithm<sup>5-8</sup>



DSM-5, Diagnostic and Statistical Manual of Mental Disorders – 5th edition.

Adapted from Oregon Pain Guidance. Tapering – Guidance & Tools. Available at www.oregonpainguidance.org/guideline/tapering/. Accessed September 23, 2020.

#### References

- Ray WA, Chung CP, Murray KT, et al. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. *JAMA*. 2016;315:2415-23.
- Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. *J Pain*. 2006;7:671-681.
- 3. Brennan MJ. Letter to the editor. J Pain. 2007;8:185.
- Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018:319:872-882.
- Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276-286.
- Oldfield BJ, Edens EL, Agnoli A, et al. Multimodal treatment options, including rotating to buprenorphine, within a multidisciplinary pain clinic for patients on risky opioid regimens: a quality improvement study. Pain Med. 2018;19(suppl 1):S38–S45.

- 7. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. US Department of Health of Human Services Web site. www.hhs.gov/opioids/sites/ default/files/2019-10/Dosage\_Reduction\_Discontinuation.pdf. October 2019. Accessed September 29, 2020.
- 8. Pain treatment guidelines. Oregon Pain Guidance Web site. www. oregonpainguidance.org/pain-treatment-guidelines/. Accessed September 29, 2020.
- Tapering BRAVO a collaborative approach clinical update March 2020. Oregon Pain Guidance Web site. www.oregonpainguidance.org/guideline/tapering/. Accessed September 29, 2020.
- How to taper patients off of chronic opioid therapy. Stanford Center for Continuing Medical Education Web site. https://stanford.cloud-cme.com/default.aspx?P=0&EID=20909. Accessed September 29, 2020.
- Chou R, Ballantyne J, Lembke A, et al. Rethinking opioid dose tapering, prescription opioid dependence, and indications for buprenorphine. *Ann Intern Med.* 2019;171:427-429.



Visit us @ mdedge.com/familymedicine

